Click Therapeutics Announces Participation in Upcoming Investor Conferences in November and December

2022-11-11

NEW YORK – November 11, 2022 – Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that company management will participate in the following investor conferences in November and December.

Jefferies London Healthcare Conference, November 15-17, 2022: David Benshoof Klein, Co-Founder and CEO, and Randall Stanicky, Chief Financial Officer, will participate in one-on-one meetings.

BTIG Digital Health Forum, November 21, 2022: Richard DeNunzio, Chief Commercial Officer, will participate in a digital therapeutics panel discussion: “The Path Forward for Prescription Digital Therapeutics: Payors, Prescribers and Pipeline” at 9 a.m. ET.

Piper Sandler 34th Annual Healthcare Conference, November 29 - December 1, 2022: Randall Stanicky will present on Tuesday, November 29, 2022 at 10:10 a.m. ET.

For additional information or to request a meeting with the company, please reach out to the respective conference organizers.

About Click Therapeutics

Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for patients with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program has entered a pivotal, fully remote, randomized, controlled trial on the Verily platform for the treatment of Major Depressive Disorder (MDD) in up to 360 adults. Click is progressing a broad pipeline of Digital Therapeutics™ across a variety of high-burden therapeutic areas, including MDD, Schizophrenia, Migraine, Chronic Pain, Atopic Dermatitis, Acute Coronary Syndrome (ACS), Obesity and more. For more information on Click, visit ClickTherapeutics.com

Company Contact

Daniel Busby
VP, Investor Relations & Strategic Finance
dbusby@clicktherapeutics.com

Media Contact

Jonni Mills jmills@clicktherapeutics.com